IVIS Spectrum Imaging System

描述（由申请人提供）：光学成像正在迅速成为生物医学研究中最通用的成像方式之一。与其他成像方式相比，光学成像的优点包括其非电离低能量辐射、用于检测微米范围内的物体的高灵敏度以及在真实的时间和完整环境中的连续数据采集。与光学成像相关联的成本、空间和时间需求低于其他成像模式，并且成像的速度和相对容易性使得这种模式对于潜在的临床应用具有吸引力。Athinoula A.位于马萨诸塞州总医院（MGH）的Martinos生物医学成像中心致力于以具有临床意义的方式开发和应用突破性的成像方法。我们的持续成功依赖于将新兴技术整合到我们现有的研究成像系统中，其中包括功能和高分辨率磁共振成像（fMRI和MRI），脑磁图（MEG），正电子发射断层扫描（PET）和自制功能光学成像仪器。新技术增强了我们验证和解释现有成像资源数据的能力，并将联合收割机成像模式用于新型多模式成像应用，这在新兴的分子成像领域尤其需要。我们建议购买一个国家的最先进的光学成像系统，能够在透射荧光，反射荧光和生物发光模式在体内，体外和体外的三维分子成像。该系统可能的光学技术的显着优势包括通过使用具有不同光谱特性的多个探针进行多通道成像的潜力;快速，简单和相对低成本的生物学假设的快速测试和在活体实验模型中的原理证明。重要的是，光学生物发光成像具有独特的优势，检测非常低的信号水平，因为它几乎无背景的光发射。凭借其操作简便、采集时间短（通常为10-60秒）以及体外（微孔板）和体内（5只小鼠，23 cm FOV）潜在的高通量格式，该创新系统还提供了高通量成像能力。新的光学系统将是许多目前资助的生物医学成像研究项目的重要资源。主要项目包括神经退行性疾病和脑功能、癌症、糖尿病和移植中的胰岛研究。有了新的体内光学成像系统和我们现有的成像设施在一个屋檐下，我们可以可行地使用一个或多个成像方式连续，甚至并行进行体内实验。该系统将成为Martinos中心和更大的MGH研究社区以及大波士顿地区其他机构丰富的跨学科研究的宝贵资源。 公共卫生相关性：获得具有荧光和生物发光能力的最先进的体内光学成像系统将允许快速，简单和廉价的方法来快速测试生物学假设和活体实验模型中的原理证明，其可以进一步用于体内药物筛选，成像报告者的开发以及癌症，神经系统疾病，糖尿病和心血管病理学的多功能动物研究。

DESCRIPTION (provided by applicant): Optical imaging is rapidly becoming one of the most versatile imaging modalities in biomedical research. The advantages of optical imaging compared to other imaging modalities include its non-ionizing low-energy radiation, high sensitivity for detecting objects in the micron range, and continuous data acquisition in real time and in an intact environment. The cost, space, and time demands associated with optical imaging are less than for other imaging modalities, and the speed and relative ease of imaging makes this modality attractive for potential clinical applications. The Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital (MGH) strives to develop and apply breakthrough imaging approaches in clinically meaningful ways. Our continuing success relies on the integration of new and emerging technologies into our existing research imaging repertoire, which includes functional and high-resolution magnetic resonance imaging (fMRI and MRI), magnetoencephalography (MEG), positron emission tomography (PET), and homebuilt functional optical imaging instrumentation. New technologies enhance our ability to validate and interpret data from our existing imaging resources and to combine imaging modalities for novel multimodal imaging applications-capabilities that are particularly needed in the emerging field of molecular imaging. We propose to purchase a state-of-the-art optical imaging system capable of 3D molecular imaging in transmission fluorescence, reflectance fluorescence, and bioluminescence modes in vivo, ex vivo, and in vitro. Significant advantages of the optical techniques possible with this system include the potential for multichannel imaging by using multiple probes with different spectral characteristics; quick, easy, and relatively low-cost rapid testing of biological hypotheses and proofs of principle in living experimental models. Importantly, optical bioluminescence imaging has unique advantages for detection of very low levels of signal because of its virtually background-free light emission. With its ease of operation, short acquisition time (typically 10-60 sec), and potential high-throughput format in vitro (microplates) and in vivo (5 mice, 23 cm FOV), this innovative system also provides high-throughput imaging capabilities. The new optical system will be an important resource for many currently funded biomedical imaging research projects. Major projects include studies on neurodenenerative disorders and brain function, cancer, and pancreatic islets in diabetes and transplantation. With the new in vivo optical imaging system and our existing imaging facilities under one roof, we can feasibly perform in-vivo experiments using one or more imaging modalities in succession, or even in parallel. This system will be an invaluable resource for the rich body of interdisciplinary research at the Martinos center and the larger MGH research community, as well as at other institutions in the greater Boston area. PUBLIC HEALTH RELEVANCE: Acquiring of a state-of-the-art in vivo optical imaging system with fluorescence and bioluminescence capabilities will allow for fast, easy and cheap ways to rapidly test biological hypotheses and proofs of principle in living experimental models, which could be further utilized for in vivo drug screening, development of imaging reporters and versatile animal studies in cancer, neurological disorders, diabetes and cardiovascular pathologies.